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Purpose: To evaluate whether 18F-fluoroethyltyrosine (FET) PET can dis-
criminate progression from pseudoprogression of brain metastases in patients
with non–small cell lung cancer undergoing immunotherapy and radiotherapy
to the brain.
Methods: Retrospective analysis of 18F-FET PET scans in cases with docu-
mented progression of brain metastases on MRI in a cohort of 53 patients with
non–small cell lung cancer receiving immune-checkpoint inhibitors and radio-
therapy of brain metastases at the University Hospital of Zürich from June
2015 until January 2019. Response to radiotherapy was assessed by MRI. In
case of equivocal findings and/or radiological progression in clinically asymp-
tomatic patients, further assessment with 18F-FET PETwas performed.
Results: From the cohort of 53 patients, the restaging MRI showed in
30 patients (56.6%) progression of at least 1 treated metastasis. Thereof,
18F-FET PETwas performed in 11 patients, based on the absence of neuro-
logical symptoms or presence of systemic response and physicians' decision.
18F-FET PET correctly identified pseudoprogression in 9 of 11 patients
(81.8%). In patients who did not undergo 18F-FET PET, 5 of 19 (26.3%) were
diagnosed with pseudoprogression.
Conclusions: Pseudoprogression of brain metastases occurred in 50% of
patients diagnosed with progression onMRI. 18F-FET PET may help differ-
entiate pseudoprogression from real progression in order to avoid discontin-
uation of effective therapy or unneeded interventions.
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R ecent phase III trials with immune-checkpoint inhibitors (ICIs)for advanced non–small cell lung cancer (NSCLC) included a
small number of patients with stable and previously treated brain
metastases.1,2 Systemic pseudoprogression, defined as initial ra-
diological enlargement of lesions followed by spontaneous de-
crease in size or stabilization, due to immune-cell infiltrate, is
reported to occur in approximately 5% of NSCLC patients.3–5
The Immunotherapy Response Assessment for Neuro-Oncology
criteria have been developed to evaluate response to immunotherapy
in the brain. Based on the Immunotherapy Response Assessment for
Neuro-Oncology criteria, suspicion of progressive disease within
6 months after the start of immunotherapy (eg, tumor progression
or appearance of new lesions) requires confirmation of tumor pro-
gression with further follow-up imaging, while immunotherapy
should be continued until true progression is confirmed.6 One case
of pseudoprogression of brain metastases under immunotherapy
has been described in a melanoma patient.7 Pseudoprogression may
also occur with gliomas after effective treatment.8–11 High-dose ra-
diotherapy as radiosurgery or stereotactic radiotherapy may induce
pseudoprogression in 2% to 30% of cases.12 Moreover, higher rates
of symptomatic radiation necrosis have been reported after stereotac-
tic radiotherapy in patients receiving immunotherapy.13
PET using 18F-FDG as radiotracer is indicated for whole-
body assessment of NSCLC patients but is not as useful for brain
metastases, owing to high physiologic background activity there.
O-(2-(18F)-fluoroethyl)-L-tyrosine PET (18F-FET PET) might dis-
criminate pseudoprogression from real progression of brain lesions,
based on uptake ratios and dynamic uptake patterns.14 FET uptake
occurs through large neutral amino acid transporters (LATs)15
(Fig. 1), which are expressed on tumor cells and immune cells.
Fluoroethyltyrosine is transported by LAT2, which is not expressed
in inflammatory cells, but to a high extent on tumor cells (Fig. 2).
Thus, FET is selectively taken up by tumor cells, which16–18 advo-
cates FET as a valuable tracer for the discrimination of neoplastic
and inflammatory lesions.19,20
The aim of this study was to evaluate the ability of 18F-FET
PET to distinguish pseudoprogression from real progression of
brain metastases in NSCLC patients treated with radiotherapy
and immunotherapy.
PATIENTS AND METHODS
Study Design and Patients
We evaluated the use of 18F-FET PET in cases with docu-
mented progression of brain metastases on MRI in a retrospective
cohort of 53 patients with NSCLC receiving ICIs and radiotherapy
of brain metastases at the University Hospital of Zürich between
June 2015 and January 2019. Our study was approved by the local
ethics committee (EK-ZH-2017-00152 and EK-ZH-2018-01919)
and is in accordance with local laws and regulations.
Imaging
All MRIs were performed as standard of care between 6
and 8 weeks after the last radiotherapy, including the following
pulse sequence set: T2-weighted, FLAIR-weighted, susceptibility-
weighted, T1-weighted with and without gadolinium contrast and
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diffusion-weighted images (Skyra Magnetom 3 T [Siemens,
Forchheim, Germany]; Ingenia 3 T [Philips, Best, The Netherlands]).
18F-FET PETexaminations were acquired using a Discovery
690 Standard scanner (GE Healthcare, Waukesha, WI) or a Signa
PET/MR scanner (GE Healthcare). A standardized dose of
130 MBq of 18F-FETwas injected. The dynamic 18F-FET PET ac-
quisition started either immediately (PET/MR) or at 20 minutes af-
ter tracer injection (PET/CT), using eight or four 5-minute frames,
respectively. For assessing the dynamic 18F-FET uptake pattern,
the 4 frames from 20 to 40 minutes were plotted, following the recom-
mendation of the 2018 joint Response Assessment inNeuro-oncology/
European Association of Neuro-Oncology/European Association of
Nuclear Medicine guidelines.21–24 The dynamic FET uptake pattern,
SUVmax, and mean and maximum target-to-background ratio
(TBRmean, TBRmax), as well as time-to-peak (TTP) were analyzed.
Based on previous publications,25,26 the following parameters were
considered to indicate progression rather than pseudoprogression:
TBRmean greater than 1.95 with 18F-FETwashout or plateau up-
take pattern or TBRmax greater than 2.55, regardless of uptake pat-
tern, as well as a shorter TTP. Follow-up MRI was routinely
performed 4 to 8 weeks after 18F-FET PET.
RESULTS
Forty-one (77.4%) patients had adenocarcinoma, 9 (17%)
had squamous cell carcinoma, 2 (3.8%) had undifferentiated carci-
noma, and 1 (1.9%) had large cell neuroendocrine carcinoma.
Thirty-three patients (62.3%) were treated with nivolumab, 12
(22.6%) with pembrolizumab, 5 (9.4%) with ipilimumab-nivolumab,
2 (3.8%) with atezolizumab, and 1 (1.9%) with nivolumab and anti–
LAG-3 antibody. Twenty-three patients (43.4%) were alive at the last
follow-up, and 30 (56.6%) died due to NSCLC. Among these 23 alive
patients, 11 (47.8%) had a metabolic complete remission of systemic
disease, 10 (43.5%) were in partial remission, and 2 (8.7%) had
progressive disease at the end of follow-up. The median overall
survival from the beginning of immunotherapy was 17.7 months
(95% confidence interval, 13.4–22.1 months). The median over-
all survival among the 23 alive patients was 20.7 months
(range, 2.49–44.3 months).
All patients underwent radiotherapy for brain metastases.
Thirty-two (60.4%) received a single course, 16 (30.2%) received
2 courses, and 5 (9.4%) received 3 or more, with a total of 80 treat-
ments performed. Forty-three treatments (53.7%) consisted of ra-
diosurgery, 25 (31.3%) of hypofractionated stereotactic radiotherapy,
and 12 (15%) of whole-brain radiotherapy.
From the cohort of 53 patients, an MRI after radiotherapy
showed in 30 patients (56.6%) progression of at least 1 treated me-
tastases, and in 18 (34.0%) cases a partial response based on the Re-
sponse Assessment in Neuro-oncology–Brain Metastases criteria.
Of the 30 patients with MRI-documented progression, 18F-FET
PET was performed in 11 subjects, between 2 and 4 weeks after
the MRI. The decision of acquiring an 18F-FET PETwas based on
the absence of neurological symptoms or presence of systemic
response and physicians' decision. No additional MRI criteria
were used. In 9 of 11 patients (81.8%), 18F-FET PET suggested
pseudoprogression rather than progression, which was confirmed
by MRI 4 to 8 weeks later. In 1 of 11 patients (9.1%), 18F-FET PET
suggested true progression, which was, however, not confirmed
by follow-up MRIs during 20 months.
In the remaining subject (9.1%), 18F-FET PET results were
inconclusive because of borderline TBRmax and a plateau pattern
in the dynamic images; this case was confirmed as true progression
at follow-up (Figs. 3A–D, Figs. 4A–C).
Of the 19 patients, where no 18F-FET PET was performed,
follow-upMRI showed pseudoprogression in 5 cases (26.3%) (Fig. 4).
Altogether, from 30 patients with initial MRI-based diagno-
sis of progression, 50% had a pseudoprogression (Fig. 5). The median
follow-up time after 18F-FET PET was 7.8 months (range,
FIGURE 1. Fluoroethyltyrosine uptake through LAT transporter on vital tumor cell.
FIGURE 2. Lack of active uptake of FET into inflammatory and normal brain tissue, extracellular accumulation by disrupted
blood-brain barrier.
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2.3–47 months). During this period, follow-up MRIs were performed
at least every 3 months.18F-FET PET parameters are listed in Table 1.
DISCUSSION
Suspicion of progression of brain metastases may lead to dis-
continuation of an effective therapy, for example, immunotherapy,
or provoke unneeded interventions. In our cohort of 30 patients with
initially suspected progression in MRI, 23 were alive at the end of
follow-up, thereof 11 (47.8%) had a complete remission of systemic
disease and 10 (43.5%) were in good partial remission under continuing
treatment with ICIs at the end of follow-up. It is therefore of paramount
importance to use tools that accurately identify pseudoprogression
in patients undergoing immunotherapy.
Pseudoprogression of brain lesions, observed as radiological
enlargement followed by spontaneous decrease in size or stabiliza-
tion, may occur after effective treatment, such as immunotherapy,
radiation therapy, or a combination of both. In our cohort, all pa-
tients received both immunotherapy and brain irradiation; hence,
observed pseudoprogressions in our cohort may be regarded as ra-
diation necrosis. Martin et al13 have reported higher rates of radia-
tion necrosis in patients undergoing brain-directed radiotherapy
and simultaneous systemic immunotherapy.
The MRI-based assessment of irradiated brain metastases
is challenging. Metastases typically cause a disruption of the
blood-brain barrier, leading to contrast enhancement on MRI.
The same mechanism is responsible for contrast enhancement
of radionecrosis, making the differentiation between real progres-
sion and pseudoprogression difficult.
Perfusion-weighted MRI with dynamic susceptibility con-
trast technique is one of the most important methods to discriminate
progression from radionecrosis.18 The relative cerebral blood vol-
ume was shown useful in the distinction of active tumor lesions
and radionecrosis, with tumor exhibiting higher relative cerebral blood
volume. Nevertheless, hypoxia due to radiation necrosis may also in-
duce neoangiogenesis, making a proper distinction difficult.27 MRI
spectroscopy using ratios of choline/creatine and/or choline/N-acetyl
aspartate may contribute to a better distinction of radionecrosis, but is
limited in small lesions and in the posterior fossa.18,28A combination
of 18F-FET PETand perfusion-weightedMRI was shown to improve
FIGURE 3. A and B, MRI and 18F-FET PET/MRI images of
a patient with real progression. C, Dynamic 18F-FET
“washout” pattern of the same patient. D, Small clusters
of epithelial tumor cells (arrow) within reactive brain
parenchyma in resected brain metastasis from the
same patient.
FIGURE 4. A and B, MRI and 18F-FET PET/MRI images of a
patient with pseudoprogression. C, Dynamic 18F-FET
“wash-in” pattern of the same patient.
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the accuracy of glioma grading compared with MRI alone.29 Spe-
cific literature data on the use of this combined technique for radi-
ation necrosis vs vital brain metastases are currently lacking.
18F-FET PET data are acquired dynamically during a compa-
rably long time of at least 20 minutes. A continuous slow accumu-
lation of tracer typically represents a disrupted blood-brain barrier,
with the radiotracer being trapped in the interstitium. On the other
hand, a rapid early uptake followed by washout of activity repre-
sents active transport, requiring vital tumor tissue.
In our series, pseudoprogression occurred in 50% of patients,
who were previously diagnosed as progressive on MRI. This is a
fundamental information for clinicians who may safely continue
treatment without additional intervention on brain metastasis. In
our study, 18F-FET PET, where performed, identified 90% of pa-
tients with pseudoprogression.
The limitations of our study are the comparably small number
of patients and the clinical preselection of subjects who underwent
18F-FET PET, which relied on systemic response and absence of
neurological symptoms. Another limitation is that we do not report
on perfusion-weighted MRI. This is owing to our study design, be-
cause MRI (partly perfusion-weighted MRI) was used as identifier
of progression before 18F-FET PET.
Our study indicates that the response assessment of brainmetas-
tases might require a closer investigation, as the expected rate of
pseudoprogression in patients treated with both radiotherapy and im-
munotherapy is much higher compared with the rate expected after ra-
diotherapy alone. This is the first study to investigate the role of
18F-FET PET in NSCLC patients treated with immunotherapy and ra-
diotherapy for brain metastases, providing new insights about intracra-
nial response and strong evidence for the use of this diagnostic tool.
FIGURE 5. Flowchart on response assessment with MRI and 18F-FET PET in NSCLC patients with brain metastases. In 30 of 53
(56.6%) patients, progression on MRI was diagnosed. In 11 of these 30 patients (36.7%), 18F-FET PET was performed. In 19
(63.3%), no 18F-FET PET was performed.
TABLE 1. Summary of 18F-FET PET Findings
Patient FET PET Conclusion
Progression at
Follow-up* Target Lesions† SUVmax SUVmean TBRmax TBRmean TTP
1 Pseudoprogression No 2 3.0/3.4 2.6/2.7 2.1/2.4 1.9/1.9 7.5/7.5
2 Pseudoprogression No 1 1.7 1.7 1.9 1.9 17.5
3 Pseudoprogression No 2 1.4/1.8 1.4 1.6/2.0 1.6/1.8 17.5/17.5
4 Pseudoprogression/
inconclusive
Yes 4 2.7/2.8/3.3 2.7/2.7/3.1 1.4/1.4/1.7 1.4/1.4/1.6 17.5/17.5/17.5
5 Pseudoprogression No 2 3.5/3.7 3.0/2.8 2.5/2.6 2.1/2.0 17.5/17.5
6 Real progression No 2 3.3/3.2 2.5/2.9 3.7/3.6 2.8/3.2 7.5/7.5
7 Pseudoprogression No 2 2.5/1.8 2.2/1.7 2/1.4 1.7/1.3 40
8 Pseudoprogression No 1 2.2 1.8 2.0 1.6 17.5
9 Pseudoprogression No 2 5.1/4.7 3.2 3.6/2.3 2.3 40
10 Pseudoprogression No 2 2.7/2.6 2.2 3.4/3.3 2.8 40
11 Pseudoprogression No 1 1.4 1.2 1.9 1.6 40
*Progression or brain metastases as assessed per follow-up MRI.
†Brain metastases treated with radiotherapy and assessed with 18F-FET PET.
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Based on our data, we have designed a prospective clinical trial com-
paring the use of MRI and 18F-FET PET in this population of patients.
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